Reduce Clinical Trial Agreement Delays
Before They Slow Study Start-Up
Download a practical playbook for biotech clinical operations, legal,
and development leaders managing US and global site contracting complexity.
Why download this playbook?
Clinical Trial Agreement delays often surface late, but affect start-up early.
For emerging biotech teams, the impact can be significant:
- delayed site activation
- slower budget finalization
- less predictable timelines
- increased cross-functional friction
- greater complexity as studies expand beyond the US
This playbook explains where delays come from and what organizations can do to improve speed, predictability, and execution discipline.

Who this is for
For biotech teams preparing for first ex-US studies, scaling site activation, or dealing with delays in contract execution.
What’s inside
- Why CTA execution has become a strategic study start-up issue
- Why the US remains highly variable despite market maturity
- What changes when biotech teams expand beyond the US
- What Europe’s contracting landscape reveals about delay and opportunity
- Lessons from Germany, France, the Netherlands, and Poland
- The 8 root causes of CTA delay across regions
- The 7 levers of faster, more predictable CTA execution
- Practical steps biotech teams can take now

Why this matters now
Contract and budget negotiations are the #1 study start-up challenge in Europe.
In 75% of European Member States, CTA execution takes more than 90 days.
Europe aims for two-thirds of clinical trials to begin recruiting within 200 days from application submission.
Faster regulatory review alone will not solve start-up delay if contracting remains slow.
This makes contracting not just a legal issue, but a strategic operational issue
for biotech teams building or scaling clinical development programs.
Also coming soon:
A cross-functional roundtable for biotech legal, regulatory/start-up, and clinical operations leaders:
Faster Contracts, Faster Activation
Be the first to hear when registration opens >> Follow us on LinkedIn
